Difference between revisions of "Team:Austin UTexas/Results"

Line 210: Line 210:
  
  
 +
</html>
 +
[[File:T--Austin_UTexas--PromgadBgel.jpg|thumb|center|700px|Figure 7. Gel results for colony PCR of P8/<i>gadB</i> and P32/<i>gadB</i> non-fluorescent transformants. The primer pair used for this PCR experiment targeted the region of the cassette plasmid containing the DNA inserts (i.e. connectors, P8/P32 promoters, <i>gadB</i> gene, and M13 terminator). The expected band length was 2 kb. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control. Lanes 3-5 contain the PCR products from three p8/<i>gadB</i> colonies. Lanes 6-8 contain the PCR products from three p8/<i>gadB</i> colonies. Evidently, all of the picked colonies were positive for the desired amplified region.]]
 +
<html>
  
  
  
<p>Along with being one of the canonical amino acids utilized in protein synthesis, glutamate plays an important role as the main amino-group donor in the biosynthesis of nitrogen-containing compounds such as amino acids and nucleotides (4, 5). Thus, we hypothesized that <i>gadB</i> overexpression via the P8 and P32 constitutive promoters and the high-copy number ColE1 origin induced a high metabolic load on the cells by shunting away glutamate from essential anabolic pathways. We believed that transformants containing the mutationally degraded <i>gadB</i> gene were selected for. In contrast, transformants containing the functional <i>gadB</i> gene were selected against due to having a depletion of glutamate substrates needed for important cellular processes. )</p>
+
 
 +
<p>inert table 1 here </p>
 +
 
  
 
<br>
 
<br>
 
<br>
 
<br>
 +
 +
 +
<p>Along with being one of the canonical amino acids utilized in protein synthesis, glutamate plays an important role as the main amino-group donor in the biosynthesis of nitrogen-containing compounds such as amino acids and nucleotides (4, 5). Thus, we hypothesized that <i>gadB</i> overexpression via the P8 and P32 constitutive promoters and the high-copy number ColE1 origin induced a high metabolic load on the cells by shunting away glutamate from essential anabolic pathways. We believed that transformants containing the mutationally degraded <i>gadB</i> gene were selected for. In contrast, transformants containing the functional <i>gadB</i> gene were selected against due to having a depletion of glutamate substrates needed for important cellular processes. </p>
 +
 +
<br>
 +
<br>
 +
 +
<p>To troubleshoot this problem, we decided to use a backbone containing the low-copy number p15A origin for the cassette assembly (Fig. 8).</p>
 +
  
 
</html>
 
</html>
[[File:T--Austin_UTexas--PromgadBgel.jpg|thumb|center|700px|Figure 7. Gel results for colony PCR of P8/<i>gadB</i> and P32/<i>gadB</i> non-fluorescent transformants. The primer pair used for this PCR experiment targeted the region of the cassette plasmid containing the DNA inserts (i.e. connectors, P8/P32 promoters, <i>gadB</i> gene, and M13 terminator). The expected band length was 2 kb. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control. Lanes 3-5 contain the PCR products from three p8/<i>gadB</i> colonies. Lanes 6-8 contain the PCR products from three p8/<i>gadB</i> colonies. Evidently, all of the picked colonies were positive for the desired amplified region.]]
+
[[File:T--Austin_UTexas--TestCassetteLowCopy.jpg|thumb|center|800px|Figure 8. Golden Gate assembly process of P8/<i>gadB</i> and P32/<i>gadB</i> test cassette plasmids using a backbone containing the low-copy number p15A origin.]]
 
<html>
 
<html>
 +
 +
 +
<p>Copy number reduction of our <i>gadB</i> overexpression cassette plasmids (accomplished by replacing the ColE1 origin with the p15A origin) was expected to decrease the overall amount of <i>gadB</i> expression, thereby decreasing the metabolic load imposed on the cells and the mutation rates observed in the <i>gadB</i> gene. However, we also observed several mutations within the <i>gadB</i> gene in the potentially positive cassette plasmids sequenced. The observed mutations are detailed in Table 2.</p>
 +
 +
<p>insert a table</p>
  
  
 
<br>
 
<br>
 
<br>
 
<br>
 +
 +
<p>With our theory that <i>gadB</i>overexpression was toxic to bacterial cells, we attempted to inducibly express the <i>gadB</i> gene using the regulatory elements of the lac operon to see if controlled <i>gadB</i> expression was even possible in E. coli. Our IPTG-inducible <i>gadB</i> expression cassette plasmid was assembled using a lac promoter and operator part plasmid, the gadB gene part plasmid, the M13 terminator part plasmid, connector part plasmids, a CP25 promoter part plasmid, a lacI part plasmid, and the SpecR and p15A origin part plasmid (Figure. Under this assembled regulatory system, in the absence of IPTG (an analog of the allolactose inducer) the LacI repressor will bind to the lac operator region to block transcription of the gadB gene. When present, IPTG will act as an inducer and bind to the LacI repressor to decrease its binding affinity for the lac operator, thereby allowing for gadB expression. This IPTG-inducible system provides us with a mechanism of controlling gadB expression. Positive colonies have been identified and sequence verification is currently underway. </p>
 +
  
 
</html>
 
</html>
[[File:T--Austin_UTexas--TestCassetteLowCopy.jpg|thumb|center|800px|Figure 8. Modified Golden Gate assembly process of P8/<i>gadB</i> and P32/<i>gadB</i> test cassette plasmids using a backbone containing the low-copy number p15A origin.]]
+
[[File:https://2017.igem.org/File:T--Austin_UTexas--iptginduciblegadB.jpg|Figure 8. Golden Gate assembly process of IPTG-inducible <i>gadB</i> expression cassette plasmid using <i>lac</i> regulatory elements.]]
 
<html>
 
<html>
 +
  
  
Line 236: Line 259:
 
</div>
 
</div>
  
<h2 style="font-family: verdana; font-size: 35px">Creating a Golden Gate compatible vector</h2>
+
<h2 style="font-family: verdana; font-size: 35px">Creating a Golden Gate compatible shuttle vector</h2>
  
<p style="font-family: verdana">After confirming <i>gadB</i> overexpression in <i>E. coli</i>, we want to assemble our final GABA overexpression cassette plasmid using the vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in <i>E. coli</i> and a pAMb1 origin for replication in Gram-positive bacteria including <i>Lactobacillus</i> species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which <i>Lactobacillus plantarum</i> is naturally susceptible to (7)
+
<p style="font-family: verdana">We wanted to assemble our final GABA overexpression cassette plasmid using the vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in <i>E. coli</i> and a pAMb1 origin for replication in Gram-positive bacteria including <i>Lactobacillus</i> species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which <i>Lactobacillus plantarum</i> is naturally susceptible to (7)
  
 
<br>
 
<br>

Revision as of 03:53, 1 November 2017

div class = "column full_size_outer" id = "top">

Click on one of the images below to learn more about our results!



Golden Gate Assembly

Although bacteria can naturally synthesize GABA, we wanted to increase expression of the gadB gene and subsequently GABA production in order to imbue our probiotic with a more potent medicinal quality, with the idea that this GABA-overproducing probiotic can then be consumed by patients with bowel disorders or anxiety (1). Overexpression of the gadB gene will be accomplished by placing it under the control of either the P8 or P32 constitutive promoters from Lactococcus lactis (2). To make our GABA-producing probiotic we first needed to assemble a GABA overexpression cassette plasmid using the Golden Gate assembly method. The intention here is that bacteria containing this GABA overexpression cassette plasmid should produce high levels of GABA. In short, Golden Gate Assembly is a new cloning method that allows for the creation of a multi-part DNA assembly (i.e. cassette plasmid) in a single reaction through the use of DNA parts containing specific, predefined suffixes and prefixes with recognition sites for Type IIs restriction enzymes (e.g. BsmBI and BsaI). The specificity of these suffixes and prefixes provides directionality of the desired DNA parts during the assembly process. For our purposes, we used the MoClo Yeast Tool Kit developed by John Dueber (3).

Creating a Golden Gate compatible shuttle vector

We wanted to assemble our final GABA overexpression cassette plasmid using the vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in E. coli and a pAMb1 origin for replication in Gram-positive bacteria including Lactobacillus species (6). Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, which Lactobacillus plantarum is naturally susceptible to (7)

Figure 9. Golden Gate assembly of the GABA final overexpression cassette plasmid with the Golden Gate compatible pMSP3535 vector and the P8/P32 promoter, gadB gene, and M13 terminator part plasmids.



The process of making the pMSP3535 vector Golden Gate compatible involved two steps: 1) assembling the pMSP3535 backbone (pAMb1 origin and erythromycin resistance gene) with a new ColE1 origin; 2) assembling a gfp dropout part to the assembly of the pMSP3535 backbone and the new ColE1 origin (Fig. 10).



Figure 10. Assembly workflow for creating the Golden Gate compatible pMSP3535 backbone. The first step involves replacing the ColE1 origin in the pMSP3535 backbone with a new ColE1 origin from pYTK001 to create a pMSP3535 + ColE1 assembly. The second step involves combining the pMSP3535 + ColE1 assembly with a gfp dropout to form the final Golden Gate compatible vector to be used to create our GABA overexpression plasmid.



Since the original pMSP3535 vector contained two illegal BsaI sites within the ColE1 origin, we sought to replace this ColE1 origin with a BsaI-free one isolated from pYTK001. This assembly process involved linearizing and adding BsmBI sites and compatible overhangs to the pMSP3535 backbone and the pYTK001 ColE1 origin via PCR. After the pMSP3535 backbone and ColE1 origin were successfully amplified by PCR (Fig. 11a), they were joined together using BsmBI assembly. Diagnostic PCR was performed on pMSP3535 + ColE1 minipreps from E. coli transformants to screen for positive samples containing both the pMSP3535 backbone and the ColE1 inserts (Fig. 11b). After confirming the presence of the pMSP3535 vector and ColE1 origin, we partially sequence-confirmed the two miniprep samples.



Figure 11. (A) Agarose gel of successful PCR for the pMSP3535 backbone and the ColE1 origin. Lane 1 contains a negative PCR control. Lanes 2 and 3 contain the ColE1 origin (around 800 bp) and pMSP3535 backbone PCR products (around 4.3 kb). (B) Agarose gel of diagnostic PCR of miniprep samples from pMSP3535 + ColE1 transformants. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control for the pMSP3535 backbone, while lanes 3 and 4 contain the pMSP3535 PCR from two miniprep samples. Lane 7 contains a positive PCR control for the ColE1 origin, while lanes 8 and 9 contain the ColE1 PCR from the same two miniprep samples. Evidently, the pMSP3535 backbone and ColE1 origin is present in both tested miniprep samples.



To this pMSP3535 + ColE1 assembly, we wanted to add a gfp dropout part containing internal BsaI sites that will generate overhangs compatible with those in the P8/P32 promoter and M13 terminator part plasmids. Additionally, the incorporation of this gfp dropout part will also allow us to visually screen for positive and negative transformants based on their fluorescence. BsmBI sites and compatible overhangs were added to the gfp dropout part by PCR amplifying it from pYTK047 (Fig. 12). We have been attempting to linearize and add BsmBI sites and overhangs to the positive pMSP3535 + ColE1 assemblies via PCR, with no success. However, results from diagnostic digests suggested that our assemblies may have contained extra, undesired DNA such as IS elements (Fig. 13). Thus, as of right now, we are screening for more positive pMSP3535 + ColE1 transformants. Once we have trouble-shooted this problem, the pMSP3535 + ColE1 and the gfp dropout PCR products will be joined through BsmBI assembly to form the final Golden Gate compatible pMSP3535 vector.

Figure 12. Agarose gel of gfp dropout PCR from pYTK047. Lane 1 contains a negative PCR control. Lane 2 contains the gfp dropout PCR product with an expected band length of around 1 kb.



Figure 13. Agarose gel of pMSP3535 + ColE1 assembly diagnostic digests. Lane 1 contains the undigested plasmid assembly. Lane 2 contains the ClaI-digested plasmid with expected 400 bp and 4.6 kb bands. The actual band generated is apparently above 10 kb. Lane 3 contains the XmnI-digested plasmid with expected 200 bp, 1.5 kb, and 3.3 kb bands. The generated band sizes were 2.5 kb and 4 kb. Lane 4 contains the KpnI-digested assembly with an expected 5.1 kb band. The generated band size was 6 kb. Lane 5 contains the Bg1II-digested assembly with an expected 5.1 kb band. The generated band size was 8 kb.



Assessing erythromycin susceptibility of E. coli



Since we are creating our Golden Gate compatible pMSP3535 shuttle vector in E. coli, we wanted to determine the natural susceptibility of E. coli to erythromycin as the minimum concentration to use has not been established clearly in the literature. Thus, we performed an erythromycin minimum inhibitory concentration test in liquid LB media (Fig. 14). After one-day incubation, we observed that E. coli was resistant up to around 150 µg/mL of erythromycin. From this experiment, we have determined that the optimal erythromycin concentration for selecting against E. coli in liquid culture is around 200-250 µg/mL.



Figure 14. Erythromycin minimum inhibitory concentration tests for E. coli in liquid media. From left to right: 0 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 200 µg/mL, 250 µg/mL, 300 µg/mL, 350 µg/mL, and 400 µg/mL.